Clinical Trial Update: Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

View source ↗

Summary

Completed real-world study evaluating first-line pembrolizumab or nivolumab in HPV-positive recurrent/metastatic oropharyngeal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Hookipa Biotech GmbH | Conditions: Oropharyngeal Squamous Cell Carcinoma | Status: COMPLETED